Drug intelligence / Profile preview

chemotherapy + target therapy-Haining Health-Coming Biotech Co., Ltd.-solid tumor (advanced)

Development stage: Unknown
Lead developer: Haining Health-Coming Biotech
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
Administration: Intravenous, Oral

Overview

chemotherapy + target therapy-Haining Health-Coming Biotech Co., Ltd.-solid tumor (advanced) refers to a personalized treatment approach for patients with advanced solid tumors, where specific combinations of chemotherapy and targeted therapy are selected using the Alphacait screening system. Developed by Haining Health-Coming Biotech Co., Ltd., the Alphacait platform utilizes synthetic lethal analysis, artificial intelligence, and an accelerated RNA Speedup patient-derived xenograft (PDX) model to test various drug combinations on a patient's own tumor cells obtained via biopsy. This precision medicine strategy aims to identify the most effective regimen for each individual patient by simulating treatment responses in vitro and in vivo. The approach is currently being evaluated in a Phase 2 clinical trial to assess outcomes such as progression-free survival (PFS), objective response rate (ORR), and overall survival (OS) in subjects with advanced malignant tumors.

Other names: Alphacait-selected chemotherapy and targeted therapyChemotherapy and target therapy (Alphacait)Alphacait screening system drug combinations

Beyond the preview

Go deeper on chemotherapy + target therapy-Haining Health-Coming Biotech Co., Ltd.-solid tumor (advanced).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on chemotherapy + target therapy-Haining Health-Coming Biotech Co., Ltd.-solid tumor (advanced).

Explore the full profile